CY2020024I1 - Αναστολεiς βητα-λακταμασων - Google Patents
Αναστολεiς βητα-λακταμασωνInfo
- Publication number
- CY2020024I1 CY2020024I1 CY2020024C CY2020024C CY2020024I1 CY 2020024 I1 CY2020024 I1 CY 2020024I1 CY 2020024 C CY2020024 C CY 2020024C CY 2020024 C CY2020024 C CY 2020024C CY 2020024 I1 CY2020024 I1 CY 2020024I1
- Authority
- CY
- Cyprus
- Prior art keywords
- lactamas
- inhibitors
- beta
- lactamas inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1153308P | 2008-01-18 | 2008-01-18 | |
EP09701487.2A EP2231667B1 (en) | 2008-01-18 | 2009-01-15 | Beta-lactamase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CY2020024I1 true CY2020024I1 (el) | 2020-11-25 |
CY2020024I2 CY2020024I2 (el) | 2020-11-25 |
Family
ID=40642204
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101079T CY1114900T1 (el) | 2008-01-18 | 2013-12-03 | Αναστολεις βητα-λακταμασων |
CY20151100288T CY1116243T1 (el) | 2008-01-18 | 2015-03-23 | Αναστολεiς βητα-λακταμασων |
CY2020024C CY2020024I2 (el) | 2008-01-18 | 2020-07-15 | Αναστολεiς βητα-λακταμασων |
CY2020023C CY2020023I2 (el) | 2008-01-18 | 2020-07-15 | Αναστολεiς βητα-λακταμασων |
CY2020025C CY2020025I1 (el) | 2008-01-18 | 2020-07-15 | Αναστολεις βητα-λακταμασων |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101079T CY1114900T1 (el) | 2008-01-18 | 2013-12-03 | Αναστολεις βητα-λακταμασων |
CY20151100288T CY1116243T1 (el) | 2008-01-18 | 2015-03-23 | Αναστολεiς βητα-λακταμασων |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2020023C CY2020023I2 (el) | 2008-01-18 | 2020-07-15 | Αναστολεiς βητα-λακταμασων |
CY2020025C CY2020025I1 (el) | 2008-01-18 | 2020-07-15 | Αναστολεις βητα-λακταμασων |
Country Status (39)
Country | Link |
---|---|
US (2) | US8487093B2 (el) |
EP (2) | EP2666774B1 (el) |
JP (3) | JP5038509B2 (el) |
KR (2) | KR101800610B1 (el) |
CN (2) | CN102827067B (el) |
AU (1) | AU2009206119C1 (el) |
BR (1) | BRPI0906871B1 (el) |
CA (1) | CA2712783C (el) |
CO (1) | CO6331438A2 (el) |
CR (1) | CR11626A (el) |
CY (5) | CY1114900T1 (el) |
DK (2) | DK2231667T3 (el) |
DO (1) | DOP2010000218A (el) |
EC (2) | ECSP10010345A (el) |
ES (2) | ES2533826T3 (el) |
FR (3) | FR20C1031I2 (el) |
HK (2) | HK1143809A1 (el) |
HN (1) | HN2010001395A (el) |
HR (2) | HRP20131123T1 (el) |
HU (2) | HUS000504I2 (el) |
IL (1) | IL206395A (el) |
LT (3) | LTPA2020517I1 (el) |
LU (1) | LUC00165I2 (el) |
MA (1) | MA32025B1 (el) |
ME (1) | ME02089B (el) |
MX (1) | MX2010007823A (el) |
MY (1) | MY162532A (el) |
NI (1) | NI201000115A (el) |
NL (2) | NL301050I2 (el) |
NO (1) | NO2020024I1 (el) |
NZ (1) | NZ586861A (el) |
PL (2) | PL2666774T3 (el) |
PT (2) | PT2231667E (el) |
RS (2) | RS53862B1 (el) |
RU (1) | RU2445314C9 (el) |
SI (2) | SI2231667T1 (el) |
UA (1) | UA101966C2 (el) |
WO (1) | WO2009091856A2 (el) |
ZA (1) | ZA201005333B (el) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101800610B1 (ko) * | 2008-01-18 | 2017-11-23 | 머크 샤프 앤드 돔 코포레이션 | 베타락타마제 억제제 |
PT2603514T (pt) | 2010-08-10 | 2018-11-09 | Rempex Pharmaceuticals Inc | Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas |
SG191320A1 (en) | 2010-12-22 | 2013-07-31 | Meiji Seika Pharma Co Ltd | Optically-active diazabicyclooctane derivative and method for manufacturing same |
US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
SG195289A1 (en) * | 2011-06-17 | 2013-12-30 | Astrazeneca Ab | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
PT2748165T (pt) | 2011-08-27 | 2016-12-28 | Wockhardt Ltd | Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas |
CA2845108C (en) | 2011-08-30 | 2015-06-16 | Wockhardt Limited | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections |
WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
US9505761B2 (en) | 2011-12-02 | 2016-11-29 | Fedora Pharmaceuticals Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
AU2013207510A1 (en) * | 2012-01-06 | 2014-07-31 | The Regents Of The University Of California | Compositions, methods of use, and methods of treatment |
US8927724B2 (en) * | 2012-03-30 | 2015-01-06 | Cubist Pharmaceuticals, Inc. | Isoxazole beta-lactamase inhibitors |
US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
MX2014011827A (es) | 2012-03-30 | 2015-02-20 | Cubist Pharm Inc | Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa. |
AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
SG11201407295YA (en) | 2012-05-08 | 2014-12-30 | Codexis Inc | Biocatalysts and methods for hydroxylation of chemical compounds |
US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
ES2758507T3 (es) | 2012-05-30 | 2020-05-05 | Meiji Seika Pharma Co Ltd | Nuevo inhibidor de B-lactamasa y método para producir el mismo |
US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
BR112015003592B1 (pt) | 2012-08-25 | 2020-04-14 | Wockhardt Ltd | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas |
EP2915805A4 (en) * | 2012-11-01 | 2016-03-23 | Kaneka Corp | METHOD FOR PRODUCING AN OPTICALLY ACTIVE BICYCLIC UREA COMPOUND |
EP2928898B1 (en) | 2012-12-07 | 2021-04-14 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
UA111925C2 (uk) * | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9642869B2 (en) | 2013-01-04 | 2017-05-09 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CA2894892A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP2943204B1 (en) | 2013-01-10 | 2019-03-13 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
BR112015021186A2 (pt) * | 2013-03-08 | 2017-07-18 | Wockhardt Ltd | processo para a preparação de (2s,5r)-7-oxo-6-sulfóxi-2-[((3r)-pirrolidina-3-carbonil)-hidrazino carbonil]-1,6-diaza-biciclo[3.2.1]octano |
WO2014135931A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
JP6182621B2 (ja) * | 2013-03-08 | 2017-08-16 | ウォックハート リミテッド | (2s,5r)−硫酸モノ−{[(4−アミノピペリジン−4−イル)カルボニル]−7−オキソ−1,6−ジアザ−ビシクロ[3.2.1]オクタ−6−イル}エステルを調製するための方法 |
MX2015011723A (es) * | 2013-03-08 | 2016-06-06 | Wockhardt Ltd | Proceso para la preparacion de una sal de sodio de (2s, 5r) -2-carboxamido-7-oxo-6-sulfooxi-1,6-diaza-biciclo[3.2.1]-octano. |
NZ711327A (en) * | 2013-03-08 | 2016-06-24 | Wockhardt Ltd | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
KR101774132B1 (ko) | 2013-03-08 | 2017-09-01 | 욱크하르트 리미티드 | (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법 |
WO2014152996A1 (en) * | 2013-03-14 | 2014-09-25 | Cubist Pharmaceuticals, Inc. | Crystalline form of a beta-lactamase inhibitor |
US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
JP6427173B2 (ja) * | 2013-06-10 | 2018-11-21 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | tert−ブチル 4−((1R,2S,5R)−6−(ベンジルオキシ)−7−オキソ−1,6−ジアザビシクロ[3.2.1]オクタン−2−カルボキサミド)ピペリジン−1−カルボキシレートの調製 |
MY193210A (en) | 2013-09-24 | 2022-09-26 | Meiji Seika Pharma Co Ltd | Process for producing diazabicyclooctane derivative |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
JP6617029B2 (ja) * | 2013-10-08 | 2019-12-04 | Meiji Seikaファルマ株式会社 | ジアザビシクロオクタン誘導体の結晶とその製造法 |
EP3074397B1 (en) * | 2013-11-26 | 2019-02-13 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
WO2015148379A1 (en) | 2014-03-24 | 2015-10-01 | Novartis Ag | Monobactam organic compounds for the treatment of bacterial infections |
WO2015150890A1 (en) * | 2014-03-29 | 2015-10-08 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester |
IN2014MU01195A (el) * | 2014-03-29 | 2015-10-02 | Wockhardt Ltd | |
US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
EP4356736A2 (en) | 2014-05-05 | 2024-04-24 | Melinta Therapeutics, Inc. | Synthesis of boronate salts |
AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
JP6622721B2 (ja) | 2014-06-11 | 2019-12-18 | ベナトルクス ファーマシューティカルズ,インク. | ベータ−ラクタマーゼ阻害剤 |
US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
MX2016016666A (es) | 2014-07-01 | 2017-08-08 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
DK3221313T3 (en) * | 2014-11-17 | 2019-04-08 | Entasis Therapeutics Ltd | COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA |
WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
ES2812848T3 (es) | 2014-12-02 | 2021-03-18 | Merck Sharp & Dohme | Proceso para la preparación de 4-((2S,5R)-6-(benciloxi)-7-oxo-1,6-diazabiciclo[3.2.1]octano-2-carboxamido)piperidin-1-carboxilato de terc-butilo y análogos del mismo |
SG11201704576SA (en) | 2014-12-05 | 2017-07-28 | Meiji Seika Pharma Co Ltd | Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation |
WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CN107438610A (zh) | 2015-03-31 | 2017-12-05 | 拜欧蒂姆公司 | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
MX2017014080A (es) * | 2015-05-07 | 2018-07-06 | Mutabilis | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. |
US10399996B2 (en) | 2015-09-11 | 2019-09-03 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
CN107531709B (zh) * | 2015-09-16 | 2020-10-23 | 吉林四环制药有限公司 | β-内酰胺酶抑制剂及其用途 |
KR20180051559A (ko) | 2015-10-02 | 2018-05-16 | 주식회사 레고켐 바이오사이언스 | 베타-락타마제의 억제용 조성물 및 억제 방법 |
WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US10501464B2 (en) * | 2015-12-11 | 2019-12-10 | Wockhardt Limited | 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections |
US10472345B2 (en) | 2016-02-04 | 2019-11-12 | Merck Sharp & Dohme Corp. | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents |
TW201736370A (zh) * | 2016-03-31 | 2017-10-16 | Xuanzhu Pharma Co Ltd | 一種抗菌組合物及其用途 |
US10184117B2 (en) | 2016-06-09 | 2019-01-22 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
JP7060245B2 (ja) | 2016-06-30 | 2022-04-26 | キューペックス バイオファーマ, インコーポレイテッド | ボロン酸誘導体およびその治療的使用 |
EP3494121B1 (en) | 2016-08-04 | 2021-10-06 | Venatorx Pharmaceuticals, Inc. | Boron-containing compounds |
LT3512851T (lt) | 2016-09-16 | 2022-10-25 | Entasis Therapeutics Limited | Beta-laktamazės inhibitorių junginiai |
US10464937B2 (en) * | 2016-09-19 | 2019-11-05 | Merck Sharp & Dohme Corp. | Process for preparing beta-lactamase inhibitor hydroxylurea intermediates |
JOP20190061A1 (ar) | 2016-09-28 | 2019-03-26 | Novartis Ag | مثبطات بيتا-لاكتاماز |
CN108078982B (zh) * | 2016-11-21 | 2020-02-07 | 天津大学 | 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途 |
SG11201908181XA (en) | 2017-03-06 | 2019-10-30 | Venatorx Pharmaceuticals Inc | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
CN108619141B (zh) * | 2017-03-16 | 2021-09-10 | 山东轩竹医药科技有限公司 | 一种抗菌组合物及其用途 |
US11046694B2 (en) | 2017-05-08 | 2021-06-29 | Entasis Therapeutics, Inc. | Compounds and methods for treating bacterial infections |
US10085999B1 (en) * | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
EP3630783A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | PENICILLIN BINDING PROTEIN INHIBITORS |
CN110959008A (zh) | 2017-05-26 | 2020-04-03 | 维纳拓尔斯制药公司 | 青霉素结合蛋白抑制剂 |
MA49623A (fr) | 2017-07-21 | 2021-03-17 | Antabio Sas | Composés chimiques |
CN109568323B (zh) * | 2017-09-29 | 2022-09-30 | 吉林四环制药有限公司 | 抗菌组合物及其用途 |
JP7377545B2 (ja) | 2017-10-11 | 2023-11-10 | キューペックス バイオファーマ, インコーポレイテッド | ボロン酸誘導体およびその合成 |
CN111417633B (zh) | 2017-12-01 | 2022-05-06 | 齐鲁制药有限公司 | 一种β-内酰胺酶抑制剂的晶型及其制备方法 |
CN109956941B (zh) * | 2017-12-25 | 2020-08-04 | 新发药业有限公司 | 一种阿维巴坦的简便制备方法 |
JP7273420B2 (ja) * | 2018-01-25 | 2023-05-15 | エボポイント、バイオサイエンシズ、カンパニー、リミテッド | β-ラクタマーゼ阻害剤及びその用途 |
EP3572411A1 (en) | 2018-05-21 | 2019-11-27 | Antabio SAS | Thiazole derivatives as metallo-beta-lactamase inhibitors |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
EP3670512A1 (en) * | 2018-12-18 | 2020-06-24 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
JP7429988B2 (ja) * | 2018-08-09 | 2024-02-09 | アンタビオ エスアーエス | セリンベータ-ラクタマーゼのインヒビターとしてのジアザビシクロオクタノン |
EP3854786A4 (en) * | 2018-09-21 | 2022-09-14 | API Corporation | PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES |
JP7437847B2 (ja) * | 2018-10-01 | 2024-02-26 | アリクサ ファーマシューティカルズ、インコーポレイテッド | レレバクタムの誘導体およびその使用 |
CN111072660B (zh) * | 2018-10-22 | 2021-05-18 | 新发药业有限公司 | 一种瑞来巴坦的简便制备方法 |
CA3133071A1 (en) | 2019-03-12 | 2020-09-17 | Arixa Pharmaceuticals, Inc. | Crystalline form of an avibactam derivative |
WO2020219405A1 (en) * | 2019-04-26 | 2020-10-29 | Merck Sharp & Dohme Corp. | Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
WO2022047790A1 (en) * | 2020-09-07 | 2022-03-10 | Ningxia Academy Of Agriculture And Forestry Sciences | Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors |
CN111943950B (zh) * | 2020-09-10 | 2022-03-29 | 山东安信制药有限公司 | 一种瑞来巴坦的制备方法 |
US11814385B2 (en) | 2021-06-25 | 2023-11-14 | University Of South Florida | Small molecule inhibitors targeting Clostridioides difficile sporulation |
WO2023220324A1 (en) * | 2022-05-11 | 2023-11-16 | The Regents Of The University Of Colorado A Body Corporate | Antibiotic composition and methods of use thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4616038A (en) | 1978-07-24 | 1986-10-07 | Merck & Co., Inc. | Combination of thienamycin-type antibiotics with dipeptidase inhibitors |
US5071843A (en) | 1978-07-24 | 1991-12-10 | Merck & Co., Inc. | Combination of 2-substituted carbapenems with dipeptidase inhibitors |
US4880793A (en) | 1978-07-24 | 1989-11-14 | Merck & Co., Inc. | Combination of thienamycin-type antibiotics with dipeptidase inhibitors |
US4539208A (en) | 1980-09-17 | 1985-09-03 | Merck & Co., Inc. | Combination of thienamycin-type antibiotics with dipeptidase inhibitors |
DE59206796D1 (de) | 1991-04-11 | 1996-08-29 | Hoffmann La Roche | Beta-Lactame |
DE69416869T2 (de) | 1993-12-29 | 1999-07-01 | Pfizer | Diazabicyclische neurokinin antagonisten |
JP3199300B2 (ja) * | 1994-05-09 | 2001-08-13 | 三共株式会社 | 1−メチルカルバペネム誘導体 |
PT882728E (pt) | 1995-12-21 | 2002-11-29 | Sankyo Co | Derivados de 1-metilcarbapenem |
JP2965922B2 (ja) * | 1995-12-21 | 1999-10-18 | 三共株式会社 | 1−メチルカルバペネム誘導体 |
JP2955276B2 (ja) * | 1997-06-19 | 1999-10-04 | 三共株式会社 | 1−メチルカルバペネム誘導体を含有する抗菌剤 |
JP4490517B2 (ja) * | 1998-03-19 | 2010-06-30 | 富山化学工業株式会社 | 5−デオキシ−5−アルカノイルアミノ−β−D−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤 |
MXPA02000246A (es) | 1999-07-06 | 2003-08-20 | Methylgene Inc | Inhibidores de °-lactamasa de sulfonamidometil fosfonato. |
CZ2002498A3 (cs) | 1999-08-10 | 2002-07-17 | British Biotech Pharmaceuticals Ltd. | Deriváty kyseliny hydroxamové a N-formylhydroxylaminu a farmaceutický prostředek |
FR2812635B1 (fr) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
JP2002212182A (ja) * | 2000-11-16 | 2002-07-31 | Sankyo Co Ltd | 1−メチルカルバペネム誘導体 |
AU1521202A (en) | 2000-11-16 | 2002-05-27 | Sankyo Co | 1-methylcarbapenem derivatives |
FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
FR2835186B1 (fr) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
JP2004043438A (ja) * | 2002-05-15 | 2004-02-12 | Sankyo Co Ltd | 1−メチルカルバペネム誘導体を含有する医薬 |
US7439253B2 (en) * | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
WO2005009943A2 (en) * | 2003-07-09 | 2005-02-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
JP2008502583A (ja) | 2003-10-01 | 2008-01-31 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 抗細菌性アミド大員環 |
EP1751527A2 (en) | 2004-02-24 | 2007-02-14 | SSCI, Inc. | Analysis and screening of solid forms using the atomic pair distribution function |
MX338505B (es) * | 2005-12-07 | 2016-04-20 | Basilea Pharmaceutica Ag | Combinaciones utiles de antibioticos de monobactama con inhibidores de beta-lactamasa. |
JP2010504967A (ja) | 2006-09-27 | 2010-02-18 | メルク エンド カムパニー インコーポレーテッド | 新規なβ−ラクタマーゼ阻害剤 |
KR101800610B1 (ko) * | 2008-01-18 | 2017-11-23 | 머크 샤프 앤드 돔 코포레이션 | 베타락타마제 억제제 |
-
2009
- 2009-01-15 KR KR1020167021668A patent/KR101800610B1/ko active IP Right Grant
- 2009-01-15 CA CA2712783A patent/CA2712783C/en active Active
- 2009-01-15 SI SI200930777T patent/SI2231667T1/sl unknown
- 2009-01-15 PT PT97014872T patent/PT2231667E/pt unknown
- 2009-01-15 AU AU2009206119A patent/AU2009206119C1/en active Active
- 2009-01-15 RU RU2010134425/04A patent/RU2445314C9/ru active
- 2009-01-15 UA UAA201010164A patent/UA101966C2/ru unknown
- 2009-01-15 NZ NZ586861A patent/NZ586861A/en unknown
- 2009-01-15 ES ES13180969.1T patent/ES2533826T3/es active Active
- 2009-01-15 WO PCT/US2009/031047 patent/WO2009091856A2/en active Application Filing
- 2009-01-15 ES ES09701487T patent/ES2433744T3/es active Active
- 2009-01-15 DK DK09701487.2T patent/DK2231667T3/da active
- 2009-01-15 DK DK13180969.1T patent/DK2666774T3/en active
- 2009-01-15 MY MYPI2010003255A patent/MY162532A/en unknown
- 2009-01-15 CN CN201210277503.4A patent/CN102827067B/zh active Active
- 2009-01-15 RS RS20150154A patent/RS53862B1/en unknown
- 2009-01-15 JP JP2010543219A patent/JP5038509B2/ja active Active
- 2009-01-15 EP EP13180969.1A patent/EP2666774B1/en active Active
- 2009-01-15 PL PL13180969T patent/PL2666774T3/pl unknown
- 2009-01-15 EP EP09701487.2A patent/EP2231667B1/en active Active
- 2009-01-15 PL PL09701487T patent/PL2231667T3/pl unknown
- 2009-01-15 US US12/812,763 patent/US8487093B2/en active Active
- 2009-01-15 ME MEP-2013-511A patent/ME02089B/me unknown
- 2009-01-15 BR BRPI0906871-6A patent/BRPI0906871B1/pt active IP Right Grant
- 2009-01-15 SI SI200931147T patent/SI2666774T1/sl unknown
- 2009-01-15 RS RS20130511A patent/RS53052B/en unknown
- 2009-01-15 CN CN200980102425.0A patent/CN101918407B/zh active Active
- 2009-01-15 MX MX2010007823A patent/MX2010007823A/es active IP Right Grant
- 2009-01-15 PT PT131809691T patent/PT2666774E/pt unknown
- 2009-01-15 KR KR1020107015963A patent/KR101648728B1/ko active IP Right Grant
-
2010
- 2010-06-15 IL IL206395A patent/IL206395A/en active IP Right Grant
- 2010-06-30 NI NI201000115A patent/NI201000115A/es unknown
- 2010-07-12 HN HN2010001395A patent/HN2010001395A/es unknown
- 2010-07-15 EC EC2010010345A patent/ECSP10010345A/es unknown
- 2010-07-16 MA MA33026A patent/MA32025B1/fr unknown
- 2010-07-16 DO DO2010000218A patent/DOP2010000218A/es unknown
- 2010-07-21 CO CO10088709A patent/CO6331438A2/es active IP Right Grant
- 2010-07-27 ZA ZA2010/05333A patent/ZA201005333B/en unknown
- 2010-08-10 CR CR11626A patent/CR11626A/es unknown
- 2010-10-26 EC EC2010010568A patent/ECSP10010568A/es unknown
- 2010-11-03 HK HK10110297.7A patent/HK1143809A1/xx unknown
-
2011
- 2011-05-26 JP JP2011118249A patent/JP5597164B2/ja active Active
-
2012
- 2012-05-22 JP JP2012116243A patent/JP5422020B2/ja active Active
-
2013
- 2013-06-06 US US13/911,549 patent/US20130274475A1/en not_active Abandoned
- 2013-11-25 HR HRP20131123AT patent/HRP20131123T1/hr unknown
- 2013-12-03 CY CY20131101079T patent/CY1114900T1/el unknown
- 2013-12-07 HK HK13113644.8A patent/HK1186180A1/xx unknown
-
2015
- 2015-03-10 HR HRP20150269TT patent/HRP20150269T1/hr unknown
- 2015-03-23 CY CY20151100288T patent/CY1116243T1/el unknown
-
2020
- 2020-06-25 NL NL301050C patent/NL301050I2/nl unknown
- 2020-06-25 NL NL301051C patent/NL301051I2/nl unknown
- 2020-06-30 LU LU00165C patent/LUC00165I2/fr unknown
- 2020-07-03 LT LTPA2020517C patent/LTPA2020517I1/lt unknown
- 2020-07-03 LT LTPA2020518C patent/LTC2666774I2/lt unknown
- 2020-07-03 LT LTPA2020516C patent/LTC2231667I2/lt unknown
- 2020-07-09 HU HUS2000024C patent/HUS000504I2/hu unknown
- 2020-07-09 HU HUS2000023C patent/HUS2000023I1/hu unknown
- 2020-07-10 FR FR20C1031C patent/FR20C1031I2/fr active Active
- 2020-07-10 FR FR20C1030C patent/FR20C1030I2/fr active Active
- 2020-07-10 FR FR20C1032C patent/FR20C1032I2/fr active Active
- 2020-07-15 CY CY2020024C patent/CY2020024I2/el unknown
- 2020-07-15 CY CY2020023C patent/CY2020023I2/el unknown
- 2020-07-15 CY CY2020025C patent/CY2020025I1/el unknown
- 2020-08-10 NO NO2020024C patent/NO2020024I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2020023I2 (el) | Αναστολεiς βητα-λακταμασων | |
CY2017016I2 (el) | Αναστολεις πρωτεασωματος | |
NO2018006I1 (no) | Atezolizumab | |
BRPI0907376A2 (pt) | Fotobiorretador | |
DE602009000234D1 (de) | msignals | |
BRPI0918564A2 (pt) | inibidores | |
BRPI0914649A2 (pt) | Piprazolo-quinazolinas | |
DE602008003972D1 (de) | Sitzrücklehnungsmechanismus | |
DE602008003521D1 (de) | Sitzrücklehnungsmechanismus | |
FI20080462A0 (fi) | Einespakkaus | |
DE602008003970D1 (de) | Strahlstromkalibriersystem | |
BRPI0907522A2 (pt) | biarlamidas | |
DE112009001946A5 (de) | Mobelauszugsführung | |
DE602009000488D1 (de) | Obstvereinzelvorrichtung | |
DK2240506T3 (da) | IAP inhibitorer | |
BRPI0907863A2 (pt) | pirrolopirimidinacarboxamidas | |
DE112009000183A5 (de) | Sicherheitsvorreiber | |
BRPI0909637A2 (pt) | 2-aminoquinolinas | |
DE602009000862D1 (de) | Gehwagenbremse | |
AT507449A3 (de) | Dämmstoffbefestiger | |
DE602009001190D1 (de) | Gleichstromumrichtervorrichtung | |
DK2331548T3 (da) | Proteasehæmmere | |
DE502008003019D1 (de) | Einschraubverschraubung | |
DE102008019532B8 (de) | Ölvormischbrenner | |
FI20075320A0 (fi) | Uusia käyttökelpoisia inhibiittoreita |